Antibody-drug Conjugate Market Report

Global Antibody-drug Conjugate Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 10, 2022
  • PAGES：194
  • REPORT CODE：GMM817703
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Antibody-drug Conjugate market report explains the definition, types, applications, major countries, and major players of the Antibody-drug Conjugate market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Agensys

    • Celldex Therapeutics

    • Synthon Holding BV

    • Sanofi

    • Concortis Biotherapeutics

    By Type:

    • Adcetris

    • Kadcyla

    By End-User:

    • Breast Cancer

    • Lymphoma

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Antibody-drug Conjugate Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Antibody-drug Conjugate Outlook to 2028- Original Forecasts

    • 2.2 Antibody-drug Conjugate Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Antibody-drug Conjugate Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Antibody-drug Conjugate Market- Recent Developments

    • 6.1 Antibody-drug Conjugate Market News and Developments

    • 6.2 Antibody-drug Conjugate Market Deals Landscape

    7 Antibody-drug Conjugate Raw Materials and Cost Structure Analysis

    • 7.1 Antibody-drug Conjugate Key Raw Materials

    • 7.2 Antibody-drug Conjugate Price Trend of Key Raw Materials

    • 7.3 Antibody-drug Conjugate Key Suppliers of Raw Materials

    • 7.4 Antibody-drug Conjugate Market Concentration Rate of Raw Materials

    • 7.5 Antibody-drug Conjugate Cost Structure Analysis

      • 7.5.1 Antibody-drug Conjugate Raw Materials Analysis

      • 7.5.2 Antibody-drug Conjugate Labor Cost Analysis

      • 7.5.3 Antibody-drug Conjugate Manufacturing Expenses Analysis

    8 Global Antibody-drug Conjugate Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Antibody-drug Conjugate Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Antibody-drug Conjugate Export by Region (Top 10 Countries) (2017-2028)

    9 Global Antibody-drug Conjugate Market Outlook by Types and Applications to 2022

    • 9.1 Global Antibody-drug Conjugate Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Adcetris Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Kadcyla Consumption and Growth Rate (2017-2022)

    • 9.2 Global Antibody-drug Conjugate Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Breast Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Lymphoma Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Antibody-drug Conjugate Market Analysis and Outlook till 2022

    • 10.1 Global Antibody-drug Conjugate Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Antibody-drug Conjugate Consumption (2017-2022)

      • 10.2.2 Canada Antibody-drug Conjugate Consumption (2017-2022)

      • 10.2.3 Mexico Antibody-drug Conjugate Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.2 UK Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.3 Spain Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.4 Belgium Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.5 France Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.6 Italy Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.7 Denmark Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.8 Finland Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.9 Norway Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.10 Sweden Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.11 Poland Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.12 Russia Antibody-drug Conjugate Consumption (2017-2022)

      • 10.3.13 Turkey Antibody-drug Conjugate Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.2 Japan Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.3 India Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.4 South Korea Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.5 Pakistan Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.6 Bangladesh Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.7 Indonesia Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.8 Thailand Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.9 Singapore Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.10 Malaysia Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.11 Philippines Antibody-drug Conjugate Consumption (2017-2022)

      • 10.4.12 Vietnam Antibody-drug Conjugate Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Antibody-drug Conjugate Consumption (2017-2022)

      • 10.5.2 Colombia Antibody-drug Conjugate Consumption (2017-2022)

      • 10.5.3 Chile Antibody-drug Conjugate Consumption (2017-2022)

      • 10.5.4 Argentina Antibody-drug Conjugate Consumption (2017-2022)

      • 10.5.5 Venezuela Antibody-drug Conjugate Consumption (2017-2022)

      • 10.5.6 Peru Antibody-drug Conjugate Consumption (2017-2022)

      • 10.5.7 Puerto Rico Antibody-drug Conjugate Consumption (2017-2022)

      • 10.5.8 Ecuador Antibody-drug Conjugate Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Antibody-drug Conjugate Consumption (2017-2022)

      • 10.6.2 Kuwait Antibody-drug Conjugate Consumption (2017-2022)

      • 10.6.3 Oman Antibody-drug Conjugate Consumption (2017-2022)

      • 10.6.4 Qatar Antibody-drug Conjugate Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Antibody-drug Conjugate Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Antibody-drug Conjugate Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Antibody-drug Conjugate Consumption (2017-2022)

      • 10.7.2 South Africa Antibody-drug Conjugate Consumption (2017-2022)

      • 10.7.3 Egypt Antibody-drug Conjugate Consumption (2017-2022)

      • 10.7.4 Algeria Antibody-drug Conjugate Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Antibody-drug Conjugate Consumption (2017-2022)

      • 10.8.2 New Zealand Antibody-drug Conjugate Consumption (2017-2022)

    11 Global Antibody-drug Conjugate Competitive Analysis

    • 11.1 Agensys

      • 11.1.1 Agensys Company Details

      • 11.1.2 Agensys Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Agensys Antibody-drug Conjugate Main Business and Markets Served

      • 11.1.4 Agensys Antibody-drug Conjugate Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Celldex Therapeutics

      • 11.2.1 Celldex Therapeutics Company Details

      • 11.2.2 Celldex Therapeutics Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Celldex Therapeutics Antibody-drug Conjugate Main Business and Markets Served

      • 11.2.4 Celldex Therapeutics Antibody-drug Conjugate Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Synthon Holding BV

      • 11.3.1 Synthon Holding BV Company Details

      • 11.3.2 Synthon Holding BV Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Synthon Holding BV Antibody-drug Conjugate Main Business and Markets Served

      • 11.3.4 Synthon Holding BV Antibody-drug Conjugate Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Sanofi

      • 11.4.1 Sanofi Company Details

      • 11.4.2 Sanofi Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Sanofi Antibody-drug Conjugate Main Business and Markets Served

      • 11.4.4 Sanofi Antibody-drug Conjugate Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Concortis Biotherapeutics

      • 11.5.1 Concortis Biotherapeutics Company Details

      • 11.5.2 Concortis Biotherapeutics Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Concortis Biotherapeutics Antibody-drug Conjugate Main Business and Markets Served

      • 11.5.4 Concortis Biotherapeutics Antibody-drug Conjugate Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Antibody-drug Conjugate Market Outlook by Types and Applications to 2028

    • 12.1 Global Antibody-drug Conjugate Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Adcetris Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Kadcyla Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Antibody-drug Conjugate Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Antibody-drug Conjugate Market Analysis and Outlook to 2028

    • 13.1 Global Antibody-drug Conjugate Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.2.2 Canada Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Antibody-drug Conjugate Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.2 UK Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.3 Spain Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.5 France Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.6 Italy Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.8 Finland Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.9 Norway Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.11 Poland Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.12 Russia Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Antibody-drug Conjugate Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.2 Japan Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.3 India Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Antibody-drug Conjugate Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.5.3 Chile Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.5.6 Peru Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Antibody-drug Conjugate Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.6.3 Oman Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Antibody-drug Conjugate Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Antibody-drug Conjugate Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Antibody-drug Conjugate Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Antibody-drug Conjugate Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Antibody-drug Conjugate

    • Figure of Antibody-drug Conjugate Picture

    • Table Global Antibody-drug Conjugate Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Antibody-drug Conjugate Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Adcetris Consumption and Growth Rate (2017-2022)

    • Figure Global Kadcyla Consumption and Growth Rate (2017-2022)

    • Figure Global Breast Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Lymphoma Consumption and Growth Rate (2017-2022)

    • Figure Global Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Table North America Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Figure United States Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Canada Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Mexico Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Table Europe Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Figure Germany Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure UK Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Spain Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Belgium Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure France Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Italy Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Denmark Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Finland Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Norway Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Sweden Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Poland Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Russia Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Turkey Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Table APAC Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Figure China Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Japan Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure India Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure South Korea Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Thailand Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Singapore Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Philippines Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Table South America Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Figure Brazil Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Colombia Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Chile Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Argentina Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Peru Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Table GCC Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Figure Bahrain Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Oman Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Qatar Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Table Africa Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Figure Nigeria Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure South Africa Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Egypt Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure Algeria Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Table Oceania Antibody-drug Conjugate Consumption by Country (2017-2022)

    • Figure Australia Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Antibody-drug Conjugate Consumption and Growth Rate (2017-2022)

    • Table Agensys Company Details

    • Table Agensys Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

    • Table Agensys Antibody-drug Conjugate Main Business and Markets Served

    • Table Agensys Antibody-drug Conjugate Product Portfolio

    • Table Celldex Therapeutics Company Details

    • Table Celldex Therapeutics Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celldex Therapeutics Antibody-drug Conjugate Main Business and Markets Served

    • Table Celldex Therapeutics Antibody-drug Conjugate Product Portfolio

    • Table Synthon Holding BV Company Details

    • Table Synthon Holding BV Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

    • Table Synthon Holding BV Antibody-drug Conjugate Main Business and Markets Served

    • Table Synthon Holding BV Antibody-drug Conjugate Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Antibody-drug Conjugate Main Business and Markets Served

    • Table Sanofi Antibody-drug Conjugate Product Portfolio

    • Table Concortis Biotherapeutics Company Details

    • Table Concortis Biotherapeutics Antibody-drug Conjugate Sales, Price, Value and Gross Profit (2017-2022)

    • Table Concortis Biotherapeutics Antibody-drug Conjugate Main Business and Markets Served

    • Table Concortis Biotherapeutics Antibody-drug Conjugate Product Portfolio

    • Figure Global Adcetris Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Kadcyla Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Table North America Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Figure United States Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Figure Germany Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Figure China Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Figure Brazil Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Antibody-drug Conjugate Consumption Forecast by Country (2022-2028)

    • Figure Australia Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Antibody-drug Conjugate Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US